We serve Chemical Name:[4-(dimethoxymethyl)phenyl]methanol CAS:183057-64-9 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
![[4-(dimethoxymethyl)phenyl]methanol](https://a.dearchem.com/CAS2/183057-64-9.png)
Chemical Name:[4-(dimethoxymethyl)phenyl]methanol
CAS.NO:183057-64-9
Synonyms:p-hydroxymethylbenzaldehyde dimethylacetal;4-(Hydroxymethyl)benzaldehyde dimethyl acetal;MFCD01863763;4-(Dimethoxymethyl)benzyl alcohol;4-Hydroxymethylbenzaldehyd dimethylacetal;(4-(Dimethoxymethyl)phenyl)methanol
Molecular Formula:C10H14O3
Molecular Weight:182.21600
HS Code:2909499000
Physical and Chemical Properties:
Melting point:38-42ºC
Boiling point:260.7ºC at 760 mmHg
Density:1.097g/cm3
Index of Refraction:1.518
PSA:38.69000
Exact Mass:182.09400
LogP:1.47030
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:NONH for all modes of transpor
Packing Group:
Contact us for information like p-hydroxymethylbenzaldehyde dimethylacetal chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,(4-(Dimethoxymethyl)phenyl)methanol physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,p-hydroxymethylbenzaldehyde dimethylacetal Use and application,p-hydroxymethylbenzaldehyde dimethylacetal technical grade,usp/ep/jp grade.
Related News: OTL-101, by comparison, is designed to correct the problem by inserting working copies of the gene into a patient’s blood stem cells. 6-Isoquinolinol, 1-(4-chlorophenyl)-3-(dimethylamino)-1,4-dihydro- manufacturers Inspired by the spirit of Start with Integrity, Succeed through Action,” Innovent’s mission is to develop, manufacture and commercialize high-quality biopharmaceutical products that are affordable to ordinary people.
Established in 2011, Innovent is committed to developing, manufacturing and commercializing high-quality innovative medicines for the treatment of cancer, autoimmune, metabolic and other major diseases. On October 31, 2018, Innovent was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 01801.HK.
Since its inception, Innovent has developed a fully integrated multi-functional platform which includes R&D, CMC (Chemistry, Manufacturing, and Controls), clinical development and commercialization capabilities.
Leveraging the platform, the company has built a robust pipeline of 25 valuable assets in the fields of cancer, metabolic, autoimmune disease and other major therapeutic areas, with 5 products – TYVYT® (sintilimab injection), BYVASDA® (bevacizumab biosimilar injection), SULINNO® (adalimumab biosimilar injection), HALPRYZA® (rituximab biosimilar injection) and Pemazyre® (pemigatinib oral inhibitor) – officially approved for marketing, 1 asset’s NDA under NMPA review, sintilimab’s Biologics License Application (BLA) acceptance in the U.S., 5 assets in Phase 3 or pivotal clinical trials, and an additional 14 molecules in clinical studies.
Innovent has built an international team with advanced talent in high-end biological drug development and commercialization, including many global experts. The company has also entered into strategic collaborations with Eli Lilly and Company, Adimab, Incyte, MD Anderson Cancer Center, Hanmi and other international partners.
Innovent strives to work with many collaborators to help advance China’s biopharmaceutical industry, improve drug availability and enhance the quality of the patients’ lives. For more information, please visit (1R,4S)-1-allyl-4-methyl-2-phenyl-1,2-dihydro-6H-pyrazino[2,1-b]quinazoline-3,6(4H)-dione suppliers The manufacturing chief pointed to some of the cutting-edge technology Takeda will roll out at the upgraded facility, such as automation and robotics, plus virtual reality equipment and training. 4-(3-ethyl-5-methylisoxazol-4-yl)-N-(4-fluorophenyl)-N-isopropyl-3,5-dioxo-1,2,4-oxadiazolidine-2-carboxamide vendor & factory.
Established in 2011, Innovent is committed to developing, manufacturing and commercializing high-quality innovative medicines for the treatment of cancer, autoimmune, metabolic and other major diseases. On October 31, 2018, Innovent was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 01801.HK.
Since its inception, Innovent has developed a fully integrated multi-functional platform which includes R&D, CMC (Chemistry, Manufacturing, and Controls), clinical development and commercialization capabilities.
Leveraging the platform, the company has built a robust pipeline of 25 valuable assets in the fields of cancer, metabolic, autoimmune disease and other major therapeutic areas, with 5 products – TYVYT® (sintilimab injection), BYVASDA® (bevacizumab biosimilar injection), SULINNO® (adalimumab biosimilar injection), HALPRYZA® (rituximab biosimilar injection) and Pemazyre® (pemigatinib oral inhibitor) – officially approved for marketing, 1 asset’s NDA under NMPA review, sintilimab’s Biologics License Application (BLA) acceptance in the U.S., 5 assets in Phase 3 or pivotal clinical trials, and an additional 14 molecules in clinical studies.
Innovent has built an international team with advanced talent in high-end biological drug development and commercialization, including many global experts. The company has also entered into strategic collaborations with Eli Lilly and Company, Adimab, Incyte, MD Anderson Cancer Center, Hanmi and other international partners.
Innovent strives to work with many collaborators to help advance China’s biopharmaceutical industry, improve drug availability and enhance the quality of the patients’ lives. For more information, please visit (1R,4S)-1-allyl-4-methyl-2-phenyl-1,2-dihydro-6H-pyrazino[2,1-b]quinazoline-3,6(4H)-dione suppliers The manufacturing chief pointed to some of the cutting-edge technology Takeda will roll out at the upgraded facility, such as automation and robotics, plus virtual reality equipment and training. 4-(3-ethyl-5-methylisoxazol-4-yl)-N-(4-fluorophenyl)-N-isopropyl-3,5-dioxo-1,2,4-oxadiazolidine-2-carboxamide vendor & factory.
